Vincristine treatment triggering the expression of asymptomatic Charcot-Marie-Tooth disease

Yoram Neumann, Amos Toren*, Gideon Rechavi, Beth Seifried, Nizza G. Shoham, Mathilda Mandel, Gilli Kenet, Nechama Sharon, Menachem Sadeh, Ruth Navon

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


A 16-year-old male suffering from Ewing's sarcoma of the pelvis was treated with vincristine as part of his chemotherapeutic protocol. The boy was never known to suffer from any neurological problems. His father had a mild limp, attributed to prolonged "taxi driving," that was never investigated medically. The first course of treatment, which included 2 mg of vincristine, resulted in clinical improvement. However, at the same time the patient developed severe weakness of both upper and lower limbs, areflexia, and gradually a pes cavus deformity. Nerve conduction studies were suggestive of severe peripheral sensorimotor neuropathy, axonal and demyelinative. A definite diagnosis of Charcot-Marie-Tooth was confirmed by molecular analysis showing the typical duplication of 1.5 megabases at chromosome 17 p11.2. This unique manifestation of vincristine neurotoxicity is reported and discussed.

Original languageEnglish
Pages (from-to)280-283
Number of pages4
JournalMedical and Pediatric Oncology
Issue number4
StatePublished - Apr 1996


  • Charcot-Marie-Tooth
  • PMP-22
  • PO
  • Vincristine


Dive into the research topics of 'Vincristine treatment triggering the expression of asymptomatic Charcot-Marie-Tooth disease'. Together they form a unique fingerprint.

Cite this